Alimera Sciences, Inc., a biopharmaceutical company, has announced the commercial availability of ILUVIEN, the sustained release pharmaceutical product for the treatment of chronic diabetic macular edema, or DME, in Germany. ILUVIEN (190 micrograms intravitreal ...
[Published Individual.com - May 20 2013]